发布时间：2025-05-23
优品生物（UpingBio）是第三方科研检测中心，聚焦于生化和免疫两大领域，提供高效、专业、精准的一站式代测服务，同时还研发生产销售ELISA试剂盒、抗原、抗体等相关试剂，现库存种类抗体20000+、抗体对6000+、ELISA6000+，检测通量大、项目多、指标全、效率高。
优品生物（UpingBio）秉承着以客户需求为纲的市场理念，竭诚为您提供优质的服务和产品!
文献推荐 文章标题 过敏性紫癜患儿血清中NLR、IL-表达水平与肾脏损伤及远期复发的相关性 作者： 贾妮旦,程彩虹,卢晓红,江佳慧,袁涛； 作者单位： 安徽芜湖，皖南医学院第一附属医院； 发表期刊： 齐齐哈尔医学院学报； DOI： 0.969 /j.issn.00－56.04.09.00； 关键词： IL-33； 引用优品生物产品 IL-33; 文献推荐 文章标题 抗阻运动通过 TREM/NF-κB/STAT 信号通路调控海马小胶质细胞极化进而改善 型糖尿病小鼠认知功能障碍 作者： 张宝文，李颖，寇现娟； 作者单位： 武汉体育学院运动医学院、运动训练监控湖北省重点实验室； 发表期刊： 生理学报； DOI： 0.94/j.aps.04.004； 关键词： lba Polyclonal Antibody，TREM Polyclonal Antibody，兔抗Iba-/鼠抗TREM； 引用优品生物试剂盒 兔抗Iba-/鼠抗TREM； 文献推荐 文章标题 布地奈德雾化吸入联合甲泼尼龙对支原体肺炎患儿炎性反应及免疫功能的影响 作者： 蔡达妮； 作者单位： 福建省晋江市中西医结合医院； 发表期刊： 临床合理用药； DOI： 10.15887/j.cnki.13-1389/r.2024.22.030； 关键词： 降钙素原( PCT) 、C 反应蛋白( CＲP) 、白介素-6( IL-6) ； 引用优品生物产品 降钙素原( PCT) ； C 反应蛋白( CＲP) ； 白介素-6( IL-6)；
文献推荐 IF5.7 文章标题 Advancing bladder cancer 作者： Xiang Huang,Guotu Du,Ying Yang,Peng Su，Shicheng Chen,Chongjiong Cai , Tianyu Huang,Yu Zeng,Yonggang Tao, Demei Tian and Neng Zhang； 作者单位： 遵义医科大学附属医院； DOI： 10.3389/fimmu.2024.1430792； 发表期刊： Frontiers in Immunology； 关键词： bladder cancer,molecular subtypes,basal squamous, prognostic model, single-cell RNAsequencing,personalized treatment； 文章摘要 Bladder cancer (BLCA) was recognized as a significant public healthchallenge due to its high incidence and mortality rates. The influence ofmolecular subtypes on treatment outcomes was well-acknowledged,necessitating further exploration of their characterization and application. Thisstudy was aimed at enhancing the understanding of BLCA by mapping itsmolecular heterogeneity and developing a robust prognostic model usingsingle-cell and bulk RNA sequencing data. Additionally, immunologicalcharacteristics and personalized treatment strategies were investigatedthrough the risk score. 引用优品生物试剂盒 科研原料 TM4SF1 Polyclonal Antibody---Youpin Biotech； 文献推荐 IF27.4 文章标题 A Universal Therapeutic Vaccine Leveraging Autologous Pre-Existing Immunity to Eliminate in Situ Uniformly Engineered Heterogeneous Tumor Cells 作者： Fuhua Wu, Zhaofei Guo, Jialiang Yang, Yangsen Ou, Xiejin Xie, Hu Liao, Chenqi Guo, Yuxi Zhan, Haiping Wu, Rui Hu, Yanhua Xu, Xue Tang, Haolin Wang, Lin Ye, Penghui He, Chunting He, Lu Huang, Shuang Luo, Xun Sun, Zhenglin Yang； DOI： 10.1038/s41422-023-00848-6； 发表期刊： ADVANCED MATERIALS； 文章摘要 Tumor vaccines that activate the autologous immune system to eliminate tumor cells represent a promising approach in cancer immunotherapy. However, challenges such as tumor heterogeneity, limited antigen selection, insufficient antigen presentation, and the slow onset of de novo immune responses have resulted in poor universality and suboptimal response rates. In contrast, pathogen-specific pre-existing immunity acquired through infection or vaccination, can rapidly generate a more potent and enduring immune response upon re-encounter with the same antigen. Here, an adeno-associated virus (AAV)-based therapeutic vaccine capable of genetically modifying diverse tumor cells to uniformly overexpress and efficiently present the highly immunogenic transmembrane SARS-CoV-2 receptor binding domain (RBD), and to release RBD-enveloped virus-like particles, which awaken and enhance the RBD-specific pre-existing immunity, leading to significant tumor remission, is engineered. Mechanistically, this therapeutic vaccine leverages the robust RBD-specific pre-existing immunity and heightened antibody-mediated phagocytosis to eliminate engineered tumor cells while inducing antigen spreading, thereby provoking a more diverse tumor-specific cellular immune responses. Notably, widespread administration of vaccines against various pathogens has provided a versatile pool of pre-existing immunity that can be redirected to eradicate tumors. These findings offer a novel perspective on overcoming the limitations posed by tumor heterogeneity and personalized medicine. 引用优品生物试剂盒 YPE800094 山羊抗小鼠免疫球蛋白G1（IgG1）抗体 (FITC) ；
management: development
of a prognostic model and
personalized therapy
